Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 88c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of $3.92, $0.88 better than the analyst estimate of $3.04. Revenue for the quarter came in at $812.7 million versus the consensus estimate of $622.9 million.

As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• C.H. Robinson acquires DeSpir Logistics for $75 million